Giorgio Secreto, Paola Muti, Milena Sant, Elisabetta Meneghini, Vittorio Krogh. . (2017) Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy. 24:11, C21-C29.
Gabriella Ferrandina, Giulia Amadio, Andrea Marcellusi, Elena Azzolini, Anna Puggina, Roberta Pastorino, Walter Ricciardi, Giovanni Scambia. . (2017) Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment. 37:11, 1093-1102.
Yosuke Tarumi, Taisuke Mori, Hiroshi Matsushima, Tetsuya Kokabu, Hiroshi Tsuchiya, Jo Kitawaki. . (2017) Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report. 62.
According to Statistics Canada, nearly half of Canadians (45 % of male and 42 % of female) develop the cancer in their life and quarter of them has a terminal prognosis (Statistic Canada, 2013).
Due to increased mortality rate over a period of time, cancer became the first priority of Oncologist and health care professionals to develop any method to stop or at least limit the fast killing action of cancer....
Felix Leung, Natasha Musrap, Eleftherios P. Diamandis, Vathany Kulasingam. . (2013) Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. 1:1, 74-86.
Ananta Gurung, Tawny Hung, Jason Morin, C Blake Gilks. . (2013) Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. 62:1, 59-70.
Lei Yu, Lei Deng, Jinke Li, Yi Zhang, Lina Hu. . (2013) The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis. 128:2, 391-396.
Amanda F. Baker, Denise J. Roe, Cynthia Laughren, Janice L. Cohen, Heather M. Wright, Mary C. Clouser, Haiyan Cui, David S. Alberts, Setsuko K. Chambers. . (2013) Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer. 31:1, 160-166.
Yuji Ikeda, Masashi Takano, Katsutoshi Oda, Hiroko Kouta, Tomoko Goto, Kazuya Kudoh, Naoki Sasaki, Tsunekazu Kita, Yoshihiro Kikuchi. . (2013) Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer. 23:2, 355-360.
Susana M. Campos, Richard T. Penson, Ursula Matulonis, Neil S. Horowitz, Christin Whalen, Lauren Pereira, Karin Tyburski, Maria Roche, Jackie Szymonifka, Suzanne Berlin. . (2013) A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. 128:2, 215-220.
Shannon N. Westin, Thomas J. Herzog, Robert L. Coleman. . (2013) Investigational agents in development for the treatment of ovarian cancer. 31:1, 213-229.
M Hall, C Gourley, I McNeish, J Ledermann, M Gore, G Jayson, T Perren, G Rustin, S Kaye. . (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. 108:2, 250-258.
Robert L. Coleman, Bradley J. Monk, Anil K. Sood, Thomas J. Herzog. . (2013) Latest research and treatment of advanced-stage epithelial ovarian cancer. 10:4, 211-224.
Emma Kipps, David S. P. Tan, Stan B. Kaye. . (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. 13:4, 273-282.